Abstract
1 In eighteen subjects receiving digoxin therapy the apparent volume of distribution (Vd) of the drug has been calculated. 2 For each subject the sensitivity of the 86Rb transport mechanism of his pre-treatment erythrocytes to in vitro inhibition by digoxin has been measured (IC50). 3 The Vd of digoxin correlates both with the age of the patients and with the IC50 of their pre-treatment erythrocytes. 4 The implications of these findings are discussed in terms of the possible determinants of the Vd of digoxin. 5 Digoxin requirements may be predictable before therapy commences if IC50 measurements are performed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aronson J. K., Grahame-Smith D. G., Hallis K. F., Hibble A., Wigley F. Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol. 1977 Apr;4(2):213–221. doi: 10.1111/j.1365-2125.1977.tb00697.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cole C. H., Balfe J. W., Welt L. G. Induction of a ouabain-sensitive ATPase defect by uremic plasma. Trans Assoc Am Physicians. 1968;81:213–220. [PubMed] [Google Scholar]
- Cole C. H. Decreased ouabain-sensitive adenosine triphosphatase activity in the erythrocyte membrame of patients with chronic renal disease. Clin Sci Mol Med. 1973 Dec;45(6):775–784. doi: 10.1042/cs0450775. [DOI] [PubMed] [Google Scholar]
- Doherty J. E., Kane J. J. Clinical pharmacology of digitalis glycosides. Annu Rev Med. 1975;26:159–171. doi: 10.1146/annurev.me.26.020175.001111. [DOI] [PubMed] [Google Scholar]
- Ewy G. A., Kapadia G. G., Yao L., Lullin M., Marcus F. I. Digoxin metabolism in the elderly. Circulation. 1969 Apr;39(4):449–453. doi: 10.1161/01.cir.39.4.449. [DOI] [PubMed] [Google Scholar]
- Gardner J. D., Kilno D. R., Swartz T. J., Butler V. P., Jr Effects of digoxin-specific antibodies on accumulation and binding of digoxin by human erythrocytes. J Clin Invest. 1973 Aug;52(8):1820–1833. doi: 10.1172/JCI107364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnson B. F., Bye C., Lader S. The bioavailability of other digoxin preparations compared with tablets. Postgrad Med J. 1974 Nov;50 (Suppl 6):62–66. [PubMed] [Google Scholar]
- Koup J. R., Jusko W. J., Elwood C. M., Kohli R. K. Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther. 1975 Jul;18(1):9–21. doi: 10.1002/cpt19751819. [DOI] [PubMed] [Google Scholar]
- Platt D., Schoch P. Effect of age and cardiac glycosides on the activity of adenosine triphosphatase (ATPase) (EC 3.6.1.3) of red cell ghost membranes. Mech Ageing Dev. 1974 Nov-Dec;3(5-6):245–252. doi: 10.1016/0047-6374(74)90021-9. [DOI] [PubMed] [Google Scholar]
- SKOU J. C. ENZYMATIC BASIS FOR ACTIVE TRANSPORT OF NA+ AND K+ ACROSS CELL MEMBRANE. Physiol Rev. 1965 Jul;45:596–617. doi: 10.1152/physrev.1965.45.3.596. [DOI] [PubMed] [Google Scholar]
- Shaw T. R., Raymond K., Greenwood H. The biological availability of very rapidly dissolving digoxin tablets. Postgrad Med J. 1974 Nov;50 (Suppl 6):55–59. [PubMed] [Google Scholar]
- Smith T. W., Butler V. P., Jr, Haber E. Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. N Engl J Med. 1969 Nov 27;281(22):1212–1216. doi: 10.1056/NEJM196911272812203. [DOI] [PubMed] [Google Scholar]
- Wagner J. G., Northam J. I., Alway C. D., Carpenter O. S. Blood levels of drug at the equilibrium state after multiple dosing. Nature. 1965 Sep 18;207(5003):1301–1302. doi: 10.1038/2071301a0. [DOI] [PubMed] [Google Scholar]
- Wagner J. G., Weidler D. J., Lin Y. J. New method for detecting and quantitating pharmacokinetic drug-drug interactions applied to ethanol-propranolol. Res Commun Chem Pathol Pharmacol. 1976 Jan;13(1):9–18. [PubMed] [Google Scholar]